You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: April 4, 2026

Litigation Details for Parkervision, Inc. v. Qualcomm Incorporated (M.D. Fla. 2011)


✉ Email this page to a colleague

« Back to Dashboard


Small Molecule Drugs cited in Parkervision, Inc. v. Qualcomm Incorporated
The small molecule drug covered by the patent cited in this case is ⤷  Start Trial .

Parkervision, Inc. v. Qualcomm Incorporated Litigation Analysis

Last updated: February 18, 2026

What is the Core Dispute in Parkervision v. Qualcomm?

The central issue in Parkervision, Inc. v. Qualcomm Incorporated, Case No. 3:11-cv-00719, filed in the U.S. District Court for the Northern District of Florida, is patent infringement. Parkervision alleges that Qualcomm's wireless communication technologies infringe upon several of Parkervision's patents related to advanced wireless communication systems. Specifically, Parkervision claims that Qualcomm's products, including mobile devices and base stations that utilize Qualcomm's chipsets, embody technologies covered by Parkervision's patents, which were originally developed by Dr. Joseph L. Pirri and others. The patents in question focus on methods and apparatuses for wireless signal processing and transmission, aiming for improved efficiency and performance in wireless networks.

What Patents are at the Heart of the Litigation?

The litigation involves multiple patents owned by Parkervision. The most frequently cited patents in this dispute include:

  • U.S. Patent No. 6,961,309: Titled "High precision wireless communication system." This patent generally relates to systems and methods for enabling precision in wireless communication, particularly in relation to locating and tracking wireless devices.
  • U.S. Patent No. 6,999,762: Titled "High precision wireless communication system." This patent is a continuation of the '309 patent and also focuses on precision in wireless communication systems.
  • U.S. Patent No. 7,203,491: Titled "High precision wireless communication system." This patent is another continuation application related to the prior patents, further detailing aspects of precise wireless communication.
  • U.S. Patent No. 7,430,207: Titled "Method and apparatus for signal processing." This patent addresses methods and apparatuses for signal processing in wireless communication, aiming for enhanced performance.
  • U.S. Patent No. 7,818,020: Titled "High precision wireless communication system." This patent continues to cover aspects of high-precision wireless communication systems.

These patents, collectively referred to as the "Parkervision Patents" or the "Pirri Patents," describe technologies that Parkervision asserts are fundamental to modern wireless communication. The core of Parkervision's argument is that Qualcomm's highly successful and widely adopted wireless chipsets and related technologies directly implement the inventions claimed in these patents, constituting infringement.

What are Qualcomm's Primary Defenses?

Qualcomm has raised several defenses in response to Parkervision's infringement claims. Key defenses include:

  • Non-Infringement: Qualcomm argues that its products and technologies do not fall within the scope of the claims of Parkervision's patents. This defense involves detailed technical analysis to demonstrate that Qualcomm's implementations differ materially from the patented inventions.
  • Invalidity: Qualcomm contends that one or more of Parkervision's patents are invalid. Grounds for invalidity often include:
    • Prior Art: The invention was already known or obvious from existing technology or publications before the patent was filed. Qualcomm has presented evidence of prior art, including earlier patents, academic papers, and technical disclosures, which they argue anticipate or render obvious the claims in Parkervision's patents.
    • Lack of Novelty and Obviousness: The claims of the patents do not meet the requirements of 35 U.S.C. § 102 (novelty) or 35 U.S.C. § 103 (non-obviousness).
    • Indefiniteness: The patent claims are not clearly defined, making it impossible to determine the scope of the invention.
  • License: Qualcomm has also argued that certain of its products might be covered by licenses from third parties, although this defense is less central than non-infringement and invalidity.
  • Prior Agreements: In some instances, Qualcomm has asserted that prior agreements or settlements with Parkervision might limit the scope of current claims, though this has been less prominent in the main litigation.

Qualcomm's strategy has involved extensive technical challenges to the validity and infringement of the asserted patents, often leading to lengthy and complex court proceedings.

How Has the Litigation Evolved Over Time?

The Parkervision v. Qualcomm litigation has a protracted history, marked by multiple filings, appeals, and key decisions.

  • Initial Filings: Parkervision first sued Qualcomm for infringement of its wireless patents in 2011. This initial wave of litigation set the stage for subsequent disputes.
  • Inter Partes Review (IPR): A significant development in patent litigation is the Inter Partes Review (IPR) process at the U.S. Patent and Trademark Office (USPTO). Qualcomm initiated IPR proceedings against several of Parkervision's asserted patents. The Patent Trial and Appeal Board (PTAB) reviewed the validity of these patents.
    • PTAB Decisions: The PTAB issued rulings in several IPRs. In some cases, the PTAB found certain claims of Parkervision's patents unpatentable, often due to prior art. For example, in IPR2014-00370 concerning U.S. Patent No. 6,999,762, the PTAB found claims unpatentable. Similar outcomes occurred for other patents. These PTAB decisions significantly impacted the scope of Parkervision's asserted claims.
  • Appeals: Decisions from the PTAB are subject to appeal to the U.S. Court of Appeals for the Federal Circuit (CAFC). Parkervision appealed several PTAB decisions.
    • CAFC Rulings: The CAFC has reviewed and, in some instances, overturned or affirmed PTAB decisions. The CAFC’s rulings on patentability and claim construction have been crucial in shaping the ongoing litigation. For example, the CAFC has addressed claim construction interpretations which are foundational to infringement analyses.
  • District Court Proceedings: Parallel to the USPTO and CAFC proceedings, the district court litigation has continued, often in a stay pending the outcome of the IPRs and appeals. Once PTAB and CAFC decisions were rendered, the district court would often re-evaluate infringement and damages based on the affirmed or modified patent claims.
  • Settlements and Further Filings: While specific details of any confidential settlements are not publicly available, the history of such large-scale patent disputes often involves a complex interplay of litigation, licensing negotiations, and potential resolutions. Parkervision has also pursued litigation against other companies in the wireless industry based on similar patent portfolios, creating a pattern of asserting its patent rights.

The evolution of this litigation highlights the strategic use of the IPR process to challenge patent validity, the importance of the CAFC’s appellate role in patent law, and the iterative nature of patent disputes between major technology companies.

What are the Key Legal and Technical Issues in Dispute?

The litigation involves several critical legal and technical issues:

Claim Construction (Markman Hearings)

A fundamental step in patent litigation is claim construction, where the court determines the precise meaning and scope of the patent claims. This process, often involving "Markman hearings," dictates what technology can be considered infringing. The interpretation of terms within Parkervision's patents, such as "high precision," "signal processing," and specific method steps, has been a significant point of contention. Different interpretations by the parties directly influence whether Qualcomm's technologies fall within the patent's scope.

Infringement Analysis

Once claims are construed, the court must determine if Qualcomm's accused products and methods infringe those claims, either directly or contributorily. This involves a detailed mapping of Qualcomm's technology against the construed claims. Parkervision must demonstrate that each element of a claim is present in Qualcomm's product or process. Qualcomm, conversely, argues that its technology does not meet all claim limitations.

Patent Validity Challenges

As discussed, Qualcomm has vigorously challenged the validity of Parkervision's patents. The central arguments revolve around:

  • Anticipation (35 U.S.C. § 102): Whether the claimed invention was previously known or used by others. Qualcomm presents prior art that allegedly discloses every element of a given claim.
  • Obviousness (35 U.S.C. § 103): Whether the claimed invention would have been obvious to a person of ordinary skill in the art at the time the invention was made, in light of the prior art. This involves assessing whether a skilled artisan could have combined existing knowledge to arrive at the patented invention.
  • Enablement and Written Description (35 U.S.C. § 112): Whether the patent specification adequately describes the invention and teaches someone skilled in the art how to make and use it.

The PTAB’s findings in IPRs, particularly regarding anticipation and obviousness, have played a critical role in narrowing the scope of patents and claims litigated in the district court.

Damages

If infringement is found and the patents are deemed valid, the court will determine the appropriate damages. This can include:

  • Lost Profits: Profits Parkervision would have made but for Qualcomm's infringement.
  • Reasonable Royalty: A royalty rate that a willing licensee would have paid to a willing licensor for the use of the patented technology. This often involves complex economic and technical analysis to establish a fair market value for the patent license.

The substantial market share and revenue generated by Qualcomm's wireless chipsets mean that potential damages could be significant.

What is the Current Status and Potential Ramifications?

The Parkervision v. Qualcomm litigation, while ongoing in various forms, has seen significant developments through the IPR process and subsequent appeals. PTAB decisions have invalidated numerous claims of Parkervision's asserted patents, significantly limiting the scope of the litigation. For instance, the PTAB's findings of unpatentability due to prior art in several IPR proceedings have weakened Parkervision's position on those specific claims and patents.

The Federal Circuit's review of PTAB decisions adds another layer of complexity, as its rulings can either uphold the PTAB's findings or remand cases for further proceedings. These appellate decisions are crucial in determining which claims, if any, remain valid and potentially infringed.

Given the history, the current status often involves the district court proceeding with the remaining live claims after the USPTO and appellate reviews. However, the effectiveness of Parkervision's remaining asserted claims is substantially diminished compared to the initial broad allegations.

Potential Ramifications:

  • For Parkervision: A successful outcome, even on a narrowed set of claims, could provide licensing revenue or damages. However, the extensive invalidation of claims by the USPTO presents a substantial hurdle. The company's strategy has been to assert its patent portfolio against major players in the wireless industry, seeking to establish value through litigation and licensing.
  • For Qualcomm: Continued success in defending against infringement claims and invalidating Parkervision's patents would protect its market position and avoid significant royalty payments or damages. The company's robust patent defense strategy, including the aggressive use of IPRs, has been effective in challenging patent validity.
  • For the Wireless Industry: The outcome of this and similar litigations influences the landscape of patent licensing and innovation. Broad patent assertions can create uncertainty and litigation costs for technology developers. Conversely, strong defenses and effective invalidation of weak patents can foster an environment more conducive to innovation and competition based on technological advancements rather than patent disputes. The trend towards using PTAB for patent validity challenges has become a significant factor in the cost and strategy of patent litigation.

The case exemplifies the challenges in patent litigation, particularly concerning foundational technologies in rapidly evolving fields like wireless communications, and the impact of administrative patent challenges on district court proceedings.

Key Takeaways

  • Parkervision alleges Qualcomm infringes its patents for wireless communication systems, primarily related to signal processing and precision.
  • Qualcomm's defense centers on non-infringement and the invalidity of Parkervision's patents, often citing prior art.
  • The litigation has been significantly shaped by Inter Partes Review (IPR) proceedings at the USPTO, which have invalidated many claims of Parkervision's patents.
  • Appeals to the Federal Circuit have further refined the scope of the patents in question.
  • The current status involves district court proceedings on remaining claims, with Parkervision's asserted portfolio significantly narrowed by USPTO rulings.

Frequently Asked Questions

What is the primary technology Parkervision claims Qualcomm infringes?

Parkervision's patents cover methods and apparatuses for advanced wireless communication systems, focusing on aspects like high-precision signal processing, transmission, and location tracking in wireless networks.

Has Parkervision been successful in its patent assertions against other companies?

Parkervision has a history of asserting its patent portfolio against multiple entities in the wireless technology sector, often leading to litigation or licensing agreements.

What is the significance of the Inter Partes Review (IPR) process in this case?

IPRs allowed Qualcomm to challenge the validity of Parkervision's patents before the USPTO. These proceedings have resulted in the invalidation of numerous patent claims, significantly impacting the scope of the ongoing district court litigation.

How does claim construction affect the outcome of this litigation?

Claim construction defines the precise meaning and scope of patent claims. A narrower construction of Parkervision's claims makes it harder for Parkervision to prove infringement by Qualcomm's technologies, while a broader construction would support Parkervision's case.

What are the potential financial implications for either company?

For Parkervision, a favorable outcome on remaining claims could result in significant licensing fees or damages. For Qualcomm, successfully defending against these claims could avoid substantial royalty payments and protect its market position and profitability.

Citations

[1] Parkervision, Inc. v. Qualcomm Incorporated, Case No. 3:11-cv-00719 (N.D. Fla.). [2] U.S. Patent No. 6,961,309. [3] U.S. Patent No. 6,999,762. [4] U.S. Patent No. 7,203,491. [5] U.S. Patent No. 7,430,207. [6] U.S. Patent No. 7,818,020. [7] Patent Trial and Appeal Board (PTAB) decisions concerning Parkervision patents (specific case numbers and dates vary). [8] U.S. Court of Appeals for the Federal Circuit (CAFC) decisions on appeals from PTAB rulings and district court judgments (specific case numbers and dates vary).

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.